TYK Medicines will present the research progress and results of 6 innovative drug projects at the 2023 Annual Meeting of American Association for Cancer Research (AACR 2023)

TYK Medicine TY-2699a —The first CDK7 inhibitor in China approved by FDA to conduct clinical trial

TYK Medicine TY-2699a —The first CDK7 inhibitor in China approved by FDA to conduct clinical trial

TYK Medicines has Successfully Passed the Recognition for Being a Specialized and Sophisticated Small and Medium-Sized Enterprise in Zhejiang Province

Innovative Pioneer: TYK Medicines was Selected for the Elite “100 Unicorn Talents in Technology”

Innovative Pioneer: TYK Medicines was Selected for the Elite “100 Unicorn Talents in Technology”

TYK Medicines (Zhejiang) was Recognized as a High and New Technology Enterprise

According to the relevant provisions of the "Measures for the Administration of the Recognition of

The TYK Medicines Academician Expert Workstation of Zhejiang Province was Officially Authorized and Granted

The TYK Medicines Academician Expert Workstation of Zhejiang Province was Officially Authorized and Granted